Search

Your search keyword '"Mathiassen, Ole N."' showing total 18 results
Start Over Author "Mathiassen, Ole N." Publication Year Range Last 10 years
18 results on '"Mathiassen, Ole N."'

3. Effects of renal denervation on coronary flow reserve and forearm dilation capacity in patients with treatment-resistant hypertension. A randomized, double-blinded, sham-controlled clinical trial

Author

Engholm, Morten, Bertelsen, Jannik B., Mathiassen, Ole N., Bøtker, Hans E., Vase, Henrik, Peters, Christian D., Bech, Jesper N., Buus, Niels H., Schroeder, Anne P., Rickers, Hans, Hansen, Klavs W., Poulsen, Per L., Kaltoft, Anne, and Christensen, Kent L.

Published
2018
Full Text
View/download PDF

4. Influence of intensive lipid‐lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study

Author

Mortensen, Martin B., primary, Sand, Niels‐Peter, additional, Busk, Martin, additional, Jensen, Jesper M., additional, Grove, Erik L., additional, Dey, Damini, additional, Iraqi, Nadia, additional, Updegrove, Adam, additional, Fonte, Tim, additional, Mathiassen, Ole N., additional, Hosbond, Susanne, additional, Bøtker, Hans E., additional, Leipsic, Jonathon, additional, Narula, Jagat, additional, and Nørgaard, Bjarne L., additional

Published
2022
Full Text
View/download PDF

5. Reduced leaflet motion after transcatheter aortic-valve replacement

Author

de Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won Keun, Balan, Prakash, van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H.C., Nørgaard, Bjarne L., Kofoed, Klaus F., Blanke, Philipp, Windecker, Stephan, Søndergaard, Lars, de Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won Keun, Balan, Prakash, van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H.C., Nørgaard, Bjarne L., Kofoed, Klaus F., Blanke, Philipp, Windecker, Stephan, and Søndergaard, Lars

Abstract

BACKGROUND Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known. METHODS In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a mean (±SD) of 90±15 days after randomization. The primary end point was the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed. RESULTS A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 to -1.9; P=0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5). In the main trial, the risk of death or thromboembolic events and the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively). CONCLUSIONS In a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy was more effective than an

Published
2020

6. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification

Author

Nørgaard, Bjarne L, primary, Mortensen, Martin B, additional, Parner, Erik, additional, Leipsic, Jonathon, additional, Steffensen, Flemming H, additional, Grove, Erik Lerkevang, additional, Mathiassen, Ole N, additional, Sand, Niels Peter, additional, Pedersen, Kamilla, additional, Riedl, Katharina A, additional, Engholm, Morten, additional, Bøtker, Hans Erik, additional, and Jensen, Jesper M, additional

Published
2020
Full Text
View/download PDF

7. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Author

De Backer, Ole, primary, Dangas, George D., additional, Jilaihawi, Hasan, additional, Leipsic, Jonathon A., additional, Terkelsen, Christian J., additional, Makkar, Raj, additional, Kini, Annapoorna S., additional, Veien, Karsten T., additional, Abdel-Wahab, Mohamed, additional, Kim, Won-Keun, additional, Balan, Prakash, additional, Van Mieghem, Nicolas, additional, Mathiassen, Ole N., additional, Jeger, Raban V., additional, Arnold, Martin, additional, Mehran, Roxana, additional, Guimarães, Ana H.C., additional, Nørgaard, Bjarne L., additional, Kofoed, Klaus F., additional, Blanke, Philipp, additional, Windecker, Stephan, additional, and Søndergaard, Lars, additional

Published
2020
Full Text
View/download PDF

8. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification.

Author

Nørgaard, Bjarne L, Mortensen, Martin B, Parner, Erik, Leipsic, Jonathon, Steffensen, Flemming H, Grove, Erik Lerkevang, Mathiassen, Ole N, Sand, Niels Peter, Pedersen, Kamilla, Riedl, Katharina A, Engholm, Morten, Bøtker, Hans Erik, and Jensen, Jesper M

Subjects
CORONARY arterial radiography, CALCIUM metabolism, BLOOD vessels, SCIENTIFIC observation, CORONARY artery stenosis, ANGINA pectoris, MYOCARDIAL infarction, CORONARY circulation, TREATMENT effectiveness, CORONARY artery disease, HEART function tests, CALCINOSIS, HOSPITAL care, MYOCARDIAL revascularization, DESCRIPTIVE statistics, COMPUTED tomography, CORONARY arteries, PATIENT safety, DISEASE risk factors
Abstract

Aims  This study sought to investigate outcomes following a normal CT-derived fractional flow reserve (FFRCT) result in patients with moderate stenosis and coronary artery calcification, and to describe the relationship between the extent of calcification, stenosis, and FFRCT. Methods and results Data from 975 consecutive patients suspected of chronic coronary syndrome with stenosis (30–70%) determined by computed CT angiography and FFRCT to guide downstream management decisions were reviewed. Median (range) follow-up time was 2.2 (0.5–4.2) years. Coronary artery calcium (CAC) scores were ≥400 in 25%, stenosis ≥50% in 83%, and FFRCT >0.80 in 51% of the patients. There was a lower incidence of the composite endpoint (death, myocardial infarction, hospitalization for unstable angina, and unplanned coronary revascularization) at 4.2 years in patients with any CAC and FFRCT > 0.80 vs. FFRCT ≤ 0.80 (3.9% and 8.7%, P  = 0.04), however, in patients with CAC scores ≥400 the risk difference between groups did not reach statistical significance, 4.2% vs. 9.7% (P  = 0.24). A negative relationship between CAC scores and FFRCT irrespective of stenosis severity was demonstrated. Conclusion FFRCT shows promise in identifying patients with stenosis and calcification who can be managed without further downstream testing. Moreover, an inverse relationship between CAC levels and FFRCT was demonstrated. Studies are needed to further assess the clinical utility of FFRCT in patients with extensive coronary calcification. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

9. Transcatheter Aortic Heart Valve Thrombosis:Incidence, Predisposing Factors, and Clinical Implications

Author

Hansson, Nicolaj C, Grove, Erik L, Andersen, Henning R, Leipsic, Jonathon, Mathiassen, Ole N, Jensen, Jesper M, Jensen, Kaare T, Blanke, Philipp, Leetmaa, Tina, Tang, Mariann, Krusell, Lars R, Klaaborg, Kaj E, Christiansen, Evald H, Terp, Kim, Terkelsen, Christian J, Poulsen, Steen H, Webb, John, Bøtker, Hans Erik, and Nørgaard, Bjarne L

Abstract

BACKGROUND: There is increasing focus on transcatheter heart valve (THV) thrombosis. However, there are limited data on incidence, clinical implications and predisposing factors of THV thrombosis following transcatheter aortic valve replacement (TAVR).OBJECTIVES: We assessed the incidence, potential predictors, and clinical implications of THV thrombosis determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.METHODS: Among 460 consecutive patients undergoing TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) valves, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1-3 months post-TAVR. MDCT scans were evaluated for hypo-attenuated leaflet thickening indicating THV thrombosis.RESULTS: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, while 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ between the Edwards Sapien XT and the Sapien 3 valves, 8% (14/173) vs. 6% (14/232) (p=0.42). The risk of THV thrombosis in patients not receiving warfarin was higher compared to patients receiving warfarin, 10.7% vs. 1.8%; RR, 95%CI: 6.09, 1.86-19.84. A larger THV was associated with an increased THV thrombosis risk (p=0.03). In multivariable analysis, 29 mm THV (RR, 95%CI: 2.89, 1.44-5.80) and no post-TAVR warfarin treatment (RR, 95%CI: 5.46, 1.68-17.7), independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.CONCLUSIONS: The incidence of THV thrombosis in this large study was 7%. Larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications.

Published
2016

10. Myocardial Perfusion Imaging Versus Computed Tomography Angiography–Derived Fractional Flow Reserve Testing in Stable Patients With Intermediate‐Range Coronary Lesions: Influence on Downstream Diagnostic Workflows and Invasive Angiography Findings

Author

Nørgaard, Bjarne L., primary, Gormsen, Lars C., additional, Bøtker, Hans Erik, additional, Parner, Erik, additional, Nielsen, Lene H., additional, Mathiassen, Ole N., additional, Grove, Erik L., additional, Øvrehus, Kristian A., additional, Gaur, Sara, additional, Leipsic, Jonathon, additional, Pedersen, Kamilla, additional, Terkelsen, Christian J., additional, Christiansen, Evald H., additional, Kaltoft, Anne, additional, Mæng, Michael, additional, Kristensen, Steen D., additional, Krusell, Lars R., additional, Lassen, Jens F., additional, and Jensen, Jesper M., additional

Published
2017
Full Text
View/download PDF

11. Clinical Use of Coronary CTA–Derived FFR for Decision-Making in Stable CAD

Author

Nørgaard, Bjarne L., primary, Hjort, Jakob, additional, Gaur, Sara, additional, Hansson, Nicolaj, additional, Bøtker, Hans Erik, additional, Leipsic, Jonathon, additional, Mathiassen, Ole N., additional, Grove, Erik L., additional, Pedersen, Kamilla, additional, Christiansen, Evald H., additional, Kaltoft, Anne, additional, Gormsen, Lars C., additional, Mæng, Michael, additional, Terkelsen, Christian J., additional, Kristensen, Steen D., additional, Krusell, Lars R., additional, and Jensen, Jesper M., additional

Published
2017
Full Text
View/download PDF

13. Transcatheter Aortic Valve Thrombosis

Author

Hansson, Nicolaj C., primary, Grove, Erik L., additional, Andersen, Henning R., additional, Leipsic, Jonathon, additional, Mathiassen, Ole N., additional, Jensen, Jesper M., additional, Jensen, Kaare T., additional, Blanke, Philipp, additional, Leetmaa, Tina, additional, Tang, Mariann, additional, Krusell, Lars R., additional, Klaaborg, Kaj E., additional, Christiansen, Evald H., additional, Terp, Kim, additional, Terkelsen, Christian J., additional, Poulsen, Steen H., additional, Webb, John, additional, Bøtker, Hans Erik, additional, and Nørgaard, Bjarne L., additional

Published
2016
Full Text
View/download PDF

14. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial

Author

Mathiassen, Ole N., primary, Vase, Henrik, additional, Bech, Jesper N., additional, Christensen, Kent L., additional, Buus, Niels H., additional, Schroeder, Anne P., additional, Lederballe, Ole, additional, Rickers, Hans, additional, Kampmann, Ulla, additional, Poulsen, Per L., additional, Hansen, Klavs W., additional, Btker, Hans E., additional, Peters, Christian D., additional, Engholm, Morten, additional, Bertelsen, Jannik B., additional, Lassen, Jens F., additional, Langfeldt, Sten, additional, Andersen, Gratien, additional, Pedersen, Erling B., additional, and Kaltoft, Anne, additional

Published
2016
Full Text
View/download PDF

15. 13.7 RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSION: EFFECTS ON CORONARY FLOW RESERVE AND FOREARM DILATION CAPACITY. A RANDOMIZED, DOUBLE-BLINDED, SHAM-CONTROLLED CLINICAL TRIAL

Author

Engholm, Morten, primary, Bertelsen, Jannik B., primary, Mathiassen, Ole N., primary, Vase, Henrik, primary, Bech, Jesper N., primary, Schroeder, Anne P., primary, Lederballe, Ole, primary, Rickers, Hans, primary, Peters, Christian D., primary, Kampmannf, Ulla, primary, Poulsen, Per L., primary, Langfeldt, Sten, primary, Andersen, Gratien, primary, Hansen, Klavs W., primary, Pedersen, Erling B., primary, Lassen, Jens F., primary, Boetker, Hans E., primary, Buus, Niels H., primary, Kaltoft, Anne, primary, and Christensen, Kent L., primary

Published
2016
Full Text
View/download PDF

16. TCT-89 Renal Sympathetic Denervation in Treatment Resistant Essential Hypertension. A Sham-Controlled, Double-blinded Randomized Trial (ReSET trial)

Author

Mathiassen, Ole N., primary, Bech, Jesper N., additional, Buus, Niels Henrik, additional, Christensen, Kent L., additional, Vase, Henrik, additional, Bertelsen, Jannik B., additional, Hans, Rickers, additional, Kampmann, Ulla, additional, Pedersen, Morten E., additional, Pedersen, Ole L., additional, Peters, Christian D., additional, Poulsen, Per L., additional, Lassen, Jens F., additional, Würgler, Klavs, additional, Boetker, Hans Erik, additional, Schroeder, Pauline, additional, Pedersen, Erling B., additional, and Kaltoft, Anne, additional

Published
2015
Full Text
View/download PDF

17. Renal denervation in treatment resistant hypertension: effects on coronary flow reserve and forearm dilation capacity. A randomized, double-blinded, SHAM-controlled clinical trial

Author

Engholm, Morten, Bertelsen, Jannik B., Mathiassen, Ole N., Vase, Henrik, Bech, Jesper N., Schroeder, Anne P., Lederballe, Ole, Rickers, Hans, Peters, Christian D., Kampmannf, Ulla, Poulsen, Per L., Langfeldt, Sten, Andersen, Gratien, Hansen, Klavs W., Pedersen, Erling B., Lassen, Jens F., Boetker, Hans E., Buus, Niels H., Kaltoft, Anne, and Christensen, Kent L.

Published
2016
Full Text
View/download PDF

18. Clinical outcomes following real-world computed tomography angiography-derived fractional flow reserve testing in chronic coronary syndrome patients with calcification.

Author

Nørgaard BL, Mortensen MB, Parner E, Leipsic J, Steffensen FH, Grove EL, Mathiassen ON, Sand NP, Pedersen K, Riedl KA, Engholm M, Bøtker HE, and Jensen JM

Subjects
Computed Tomography Angiography, Coronary Angiography, Coronary Vessels, Humans, Predictive Value of Tests, Severity of Illness Index, Tomography, X-Ray Computed, Coronary Artery Disease diagnostic imaging, Coronary Stenosis diagnostic imaging, Fractional Flow Reserve, Myocardial
Abstract

Aims: This study sought to investigate outcomes following a normal CT-derived fractional flow reserve (FFRCT) result in patients with moderate stenosis and coronary artery calcification, and to describe the relationship between the extent of calcification, stenosis, and FFRCT., Methods and Results: Data from 975 consecutive patients suspected of chronic coronary syndrome with stenosis (30-70%) determined by computed CT angiography and FFRCT to guide downstream management decisions were reviewed. Median (range) follow-up time was 2.2 (0.5-4.2) years. Coronary artery calcium (CAC) scores were ≥400 in 25%, stenosis ≥50% in 83%, and FFRCT >0.80 in 51% of the patients. There was a lower incidence of the composite endpoint (death, myocardial infarction, hospitalization for unstable angina, and unplanned coronary revascularization) at 4.2 years in patients with any CAC and FFRCT > 0.80 vs. FFRCT ≤ 0.80 (3.9% and 8.7%, P = 0.04), however, in patients with CAC scores ≥400 the risk difference between groups did not reach statistical significance, 4.2% vs. 9.7% (P = 0.24). A negative relationship between CAC scores and FFRCT irrespective of stenosis severity was demonstrated., Conclusion: FFRCT shows promise in identifying patients with stenosis and calcification who can be managed without further downstream testing. Moreover, an inverse relationship between CAC levels and FFRCT was demonstrated. Studies are needed to further assess the clinical utility of FFRCT in patients with extensive coronary calcification., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results